Kaleem, Safa
Zhang, Cenai
Gusdon, Aaron M.
Oh, Stephanie
Merkler, Alexander E.
Avadhani, Radhika
Awad, Isaam
Hanley, Daniel F.
Kamel, Hooman
Ziai, Wendy C.
Murthy, Santosh B. http://orcid.org/0000-0002-4950-0992
Funding for this research was provided by:
Foundation for the National Institutes of Health (K23NS105948, 5U01NS062851)
Article History
Received: 9 March 2023
Accepted: 2 June 2023
First Online: 22 June 2023
Conflict of interest
: Dr. Merkler reports personal fees for medicolegal consulting in stroke and neurological disorders. Dr. Awad is supported by the National Institutes of Health (NIH) (1U01NS080824 and U01NS106513). Dr. Hanley is supported by the NIH (U01NS080824 and U24TR001609), and reports personal fees from Op2Lysis, personal fees from BrainScope and Neurotrope, and nonfinancial support from Genentech outside the submitted work. Dr. Kamel has received grant support from the NIH, serves as Co-principal investigator (co-PI) for the NIH-funded AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA) trial (National Institute of Neurological Disorders and Stroke U01NS095869) which receives in-kind study drug from the Bristol Myers Squibb BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics, serves as Deputy Editor for <i>JAMA Neurology</i>, serves as a steering committee member of Medtronic’s Stroke atrial fibrillation (AF) trial (uncompensated), serves on an endpoint adjudication committee for a trial of empagliflozin for Boehringer-Ingelheim, and has served on an advisory board for Roivant Sciences related to Factor XI inhibition. Dr. Ziai is supported by the NIH (1U01NS080824, R01NS102583, and U01NS106513), and receives consulting fees from C.R. Bard, Inc. outside of the area of work commented on here. Dr. Murthy is supported by the NIH (K23NS105948) and has received personal fees for medicolegal consulting on neurological disorders. The other authors have nothing to disclose.
: The article adheres to ethical guidelines and indicates ethical approvals (institutional review board). The study was approved by the Weill Cornell Medicine Institutional Review Board.